Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial
Reza Malekzadeh, Atefeh Abedini, Behzad Mohsenpour, Ehsan Sharifipour, Roya Ghasemian, Seyed Ali Javad‐Mousavi, Rozita Khodashahi, Mahboobeh Darban, Saeed Kalantari, Nafiseh Abdollahi, Mohammad Reza Salehi, Abbas Rezaei Hosseinabadi, Farzin Khorvash, Melika Valizadeh, Farzaneh Dastan, Sahar Yousefian, Hamed Hosseini, Nassim Anjidani, Payam Tabarsi
Topics & Concepts
TocilizumabMedicineAdverse effectClinical endpointInternal medicineProspective cohort studyMortality rateClinical trialDiseaseCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19